The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...

The U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG’s NVS Pluvicto for prostate cancer patients. The expanded indication, which approximately triples the number of patients ...

In the PSMAfore trial, Pluvicto reduced the risk of radiographic progression or death by 59%. The Food and Drug Administration (FDA) has expanded the approval of Pluvicto ® (lutetium Lu 177 ...

for 67Cu-SAR-bisPSMA for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant pr Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or ...

Neoplastic Agents Market Report 2025" has been added to ResearchAndMarkets.com's offering.This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, ...

Men age 40 and over will be able to get screened for prostate cancer at no cost as the Urology Health Foundation holds free screenings ... called prostate-specific antigen in the blood.

The spokesperson said: “PSA stands for Prostate Specific Antigen, it is a simple blood test that measures the amount of antigen, produced by the prostate, entering the blood. It is not a direct test ...

The α2,3-sialyl N-glycosylated free prostate-specific antigen ratio (S2,3PSA%) was approved in Japan as a prostate cancer (PCa) diagnostic test. We evaluated the analytical characterization and ...

The MHRA has approved the product for three clinical settings, including identifying how far high-risk prostate cancer has ...

But just beyond the concession stands and merchandise booths, an unexpected initiative is taking place: free prostate-cancer screenings ... of shared decision-making regarding prostate-specific (PSA) ...

clinicians monitor prostate specific antigen (PSA) levels. Persistently elevated PSA levels indicate residual cancer and are linked to worse outcomes. But in a paper published in JAMA Oncology ...